Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients.
José Luis Martín-VarillasLara Sanchez-BilbaoVanesa Calvo-RíoAlfredo AdánInés HernanzAdela Gallego-FloresEmma Beltran-CatalanSonia Castro-OreiroPatricia FanloAlvaro Garcia MartosIgnacio TorreMiguel Cordero-ComaJuan Ramon De DiosÁngel García-AparicioMarisa Hernández-GarfellaAmalia Sánchez-AndradeAndrea García-ValleOlga MaizRoberto MiguélezSergio Rodríguez-MonteroAna UrruticoecheaRaúl VerozArantxa ConesaCristina Fernández-CarballidoVega JovaníJose J MondejarOlga Martínez GonzálezPatricia Moya AlvaradoSusana Romero-YustePaula Rubio-MuñozEva Peña-Sainz-PardoMarta Garijo-BufortRosalía Demetrio-PabloJose Luis Hernández-HernándezRicardo Blanco-AlonsoPublished in: RMD open (2023)
We studied 80 (33 men/47 women) patients (111 affected eyes) with a mean age of 41.6±11.7 years. The IMID included were: spondyloarthritis (n=43), Behçet's disease (n=10), psoriatic arthritis (n=8), Crohn's disease (n=4), sarcoidosis (n=2), juvenile idiopathic arthritis (n=1), reactive arthritis (n=1), rheumatoid arthritis (n=1), relapsing polychondritis (n=1), CONCLUSIONS: CZP seems to be effective and safe in uveitis related to different IMID, even in patients refractory to previous biological drugs.
Keyphrases
- juvenile idiopathic arthritis
- rheumatoid arthritis
- end stage renal disease
- disease activity
- ankylosing spondylitis
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- pregnant women
- patient reported outcomes
- study protocol
- metabolic syndrome
- systemic lupus erythematosus
- polycystic ovary syndrome
- skeletal muscle
- cross sectional
- drug induced
- interstitial lung disease